Market

Argenx Acquires Unnatural Products in Billion Dollar Deal
Research & Development Argenx Acquires Unnatural Products in Billion Dollar Deal

The acquisition of Santa Cruz-based Unnatural Products allows Argenx to integrate a proprietary platform capable of engineering macrocyclic peptides that survive the harsh environment of the human digestive tract. This strategic transaction, valued at a potential $1.1 billion, signifies a profound

How Does AI Transform Precision Medicine Intelligence?
Tech & Innovation How Does AI Transform Precision Medicine Intelligence?

The rapid evolution of the precision medicine landscape has rendered traditional, manual data gathering methods insufficient for making high-stakes strategic decisions. Historically, life science analysts were forced to navigate a fragmented sea of information, spending countless hours

How to Generate Passive Income With Healthcare REITs
Management & Regulatory How to Generate Passive Income With Healthcare REITs

The monthly dividend schedule offered by Healthpeak Properties provides investors with more frequent cash flow than the traditional quarterly cycles found in most equity markets. This specific liquidity advantage is a key component of a broader strategy involving healthcare real estate investment

Biotech Sector Volatility Hits Nurix and Karyopharm Share Prices
Research & Development Biotech Sector Volatility Hits Nurix and Karyopharm Share Prices

The recent bankruptcy filing of Karyopharm Therapeutics includes a restructuring support agreement and a $55 million debtor-in-possession financing package to maintain clinical operations. This development serves as a sobering reminder of the razor-thin margins for error that currently define the

Cencora Launches Gene Therapy Service Amid Biotech Shifts
Research & Development Cencora Launches Gene Therapy Service Amid Biotech Shifts

The Neonatal Fc receptor has emerged as a high-value target in immunology because it plays a critical role in recycling the antibodies that sustain autoimmune activity. This shift toward complex, target-specific medicine is forcing the global pharmaceutical infrastructure to evolve beyond simple

EU Pharma Reform Changes the Investment Case Before Launch
Management & Regulatory EU Pharma Reform Changes the Investment Case Before Launch

Eight years of data protection would remain, but baseline market protection would fall from two years to one under the EU’s near-final pharmaceutical overhaul. That change puts development economics alongside faster regulatory review as a board-level concern. Companies planning European programs

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later